CFB RNAi Agents With Hepatocyte-Targeted Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for complement-mediated diseases, particularly those targeting Complement Factor B (CFB), face challenges such as lack of specificity, unfavorable side effects, and delivery issues, leading to unmet medical needs in conditions like IgA nephropathy, C3 glomerulopathy, and others.
Innovation Solution
Development of chemically modified small interfering RNA (siRNA) agents conjugated with N-acetyl-galactosamine ligands for targeted delivery to hepatocytes, providing selective and efficient inhibition of CFB gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broadly-acting immunosuppressive agents are used to treat complement-mediated diseases, then disease symptoms can be suppressed, but side effects increase and specificity is reduced
Solution Approach 1:
The patent uses RNAi agents as intermediaries to specifically target CFB mRNA degradation, rather than using broadly-acting immunosuppressive agents. This intermediary approach allows selective inhibition of the complement system through CFB suppression, achieving disease treatment efficacy while avoiding the broad side effects of traditional immunosuppressants
Solution Approach 2:
The invention applies local quality by designing RNAi agents with specific chemical modifications and hepatocyte-targeting ligands that concentrate the therapeutic effect specifically at the liver where CFB is produced, while leaving other bodily systems unaffected. This localized action provides specificity and reduces systemic side effects
2Measurement precision
If current CFB-targeting therapies are developed, then complement pathway specificity is improved, but delivery issues and adherence problems persist
Solution Approach 1:
The patent introduces hepatocyte-targeting ligands as intermediaries that facilitate the delivery of RNAi agents to liver cells. This mediator approach solves the delivery issue by enabling selective uptake by hepatocytes through receptor-mediated endocytosis, improving both delivery efficiency and patient adherence
Solution Approach 2:
The invention applies parameter changes by modifying the physical and chemical properties of the RNAi agents through chemical modifications and conjugation with targeting ligands. These parameter changes enhance stability, cellular uptake, and hepatocyte specificity, thereby improving delivery and adherence
3Measurement precision
If RNAi agents with hepatocyte-targeting ligands are used, then delivery specificity to hepatocytes is improved, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the RNAi agent into distinct functional modules: the siRNA core structure for CFB mRNA targeting, chemical modification groups for stability enhancement, and hepatocyte-targeting ligand conjugates. This modular segmentation achieves high targeting precision while managing molecular complexity through systematic design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents achieve potent and specific in vivo inhibition of CFB, offering a safer and less frequent dosing regimen, reducing adverse effects and improving treatment efficacy for complement-mediated diseases.
Implementation Method 1
Each CFB RNAi agent comprises a sense strand and an antisense strand... The sense and antisense strands are annealed to form a duplex
Implementation Method 2
In some embodiments, the RNAi agent contains one or more modified nucleotides and one or more modified internucleoside linkages, e.g., one or more phosphorothioate linkages
Implementation Method 3
chemically modified small interfering RNA (siRNA) agents conjugated with N-acetyl-galactosamine ligands for targeted delivery to hepatocytes
Data Source
AI summary
The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosanine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and/or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and/or other complement-mediated diseases.